Trial Profile
A Phase 1, Open Label Study In Healthy Subjects To Investigate The Pharmacokinetics Of Pf 06865571 Following Single Oral Administration Of Immediate And Modified Release Tablets Compared To Immediate Release Oral Suspension Under Fed Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2018
Price :
$35
*
At a glance
- Drugs Ervogastat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 13 Apr 2018 Status changed from recruiting to completed.
- 24 Jan 2018 Status changed from not yet recruiting to recruiting.
- 22 Dec 2017 New trial record